3 Pharma Stocks to Watch as India's Pharma Exports Cross US$ 30 Billion

India's pharmaceutical exports crossed US$ 30 billion (bn) in FY25, according to a report in the Economic Times. Quoting the commerce secretary Rajesh Agrawal, the report added that that India remains a trusted global supplier of quality and affordable medicines.

Here are three stocks that you can watch from the pharma export space.

Please note, this is not a fundamental analysis of or recommendations on the stocks mentioned.

#1 Aurobindo Pharma

First on our list is Aurobindo Pharma.

The company specialises in the development, production, and global distribution of a diverse array of generic medications, active pharmaceutical ingredients (APIs), and injectable products, reaching over 150 countries worldwide.

The company is the top generic pharmaceutical company in the US. 89% of Aurobindo Pharma's sales come from exports, with 49% coming from the US alone.

Aurobindo Pharma Financial Snapshot (FY23 to FY25)

Source: Equitymaster

On the financial front, the company reported revenues of Rs 82,857 m in Q2 FY26, against Rs 77,961 m in the corresponding period of last year. The net profits of the company surged to Rs 8,465 m in Q2 FY26, from Rs 8,167 m YoY.

Moving ahead, Aurobindo Pharma is rapidly advancing capabilities beyond traditional generics towards leadership in high-value complex generics and specialty products.

The company continues to increase its formulations manufacturing scale, with expanded capacities across multiple locations capable of delivering over 60 billion (bn) doses annually, up from 50 bn doses.

Aurobindo Pharma is also expanding and driving growth in certain geographies. The company is focused markets like Indonesia, China, Canada, and South Africa.

The company is also deepening backward integration through strategic investments in Pen-G and 6-APA facilities to secure supply chain resilience and long-term cost efficiencies.

In the respiratory therapeutic area, the company is collaborating with a global pharma major for codeveloping respiratory products. This is a testament to its aspiration of advancing the complex respiratory area.

To know more you can click the Aurobindo Pharma fact sheet and latest quarterly results.

#2 Marksans Pharma

Next on our list is the stock of Marksans Pharma.

Marksans Pharma is a top exporter and will benefit as exports surge. The company is engaged in research, manufacturing & marketing of generic pharmaceutical formulation in the global markets.

The company's facilities have the approval of top regulatory agencies from around the world including US FDA, UK MHRA and Australian TGA.

It has a diverse product portfolio that includes therapeutic segments of cardiovascular systems, central nervous systems, antidiabetic, pain management, gastroenterological and anti-allergies.

Marksans Pharma Financial Snapshot (FY23 to FY25)

Source: Equitymaster

On the financial front revenues of the company increased to Rs 7,204 m in Q2 FY26 from Rs 6,419 m YoY. Net profits of Marksans Pharma also saw a marginal uptick to Rs 991 m from Rs 978 m YoY.

Overall, Q2 FY26 was a good quarter for the company.

The US region recorded good growth, demonstrating resilience amid macro challenges, supported by stabilizing tariff conditions, timely order book execution, and meaningful traction from new product launches.

Despite ongoing price pressure, the UK market also saw increased demand and produced steady results. Through both organic and strategic acquisitions, the company is strategically increasing its efficiency, especially in the European Union.

Moving ahead, Marksans Pharma management has set a target of Rs 30 bn in revenue over the next couple of years. The plans are to double the US OTC business and strengthen position in the UK and Europe.

#3 Gland Pharma

Next on our list is Gland Pharma.

The company is present in sterile injectables, oncology and ophthalmics, with a focus on complex injectables.

The production of complex generic injectables is based on the company's R&D expertise and manufacturing capabilities.

Gland Pharma Financial Snapshot (FY23 to FY25)

Source: Equitymaster

On the financial front revenues of the company increased to Rs 14,869 m in Q2 FY26 from Rs 14,058 m YoY. Net profits of Gland Pharma also saw a decent uptick to Rs 1,837 m from Rs 1,635 m YoY.

Moving ahead, the company's strategic priorities are centred around scaling core operations, deepening its innovation pipeline, and driving sustainable value creation.

Specifically, the company intends to enhance manufacturing capabilities with a focus on scalability, quality, and global compliance.

According to the management the emphasis would also be on accelerating innovation through a robust pipeline of complex injectables and the scale-up of our biologics CDMO platform.

Gland Pharma is also likely to explore strategic M&A to access new technologies, diversify its portfolio, and enter untapped markets.

Conclusion

Investing in pharma stocks that are exporters requires careful consideration. US FDA inspections and warning letters can delay launches and inflate costs, hitting profitability. On the other hand, pricing erosion and currency fluctuations add to volatility.

Even though some stocks from the pharma sector may have value, the tariff headwind remains. Investors need to do a thorough research before investing.

Investors should evaluate the company's fundamentals, corporate governance, and valuations of the stock as key factors when conducting due diligence before making investment decisions.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...